Revance Therapeutics (RVNC) Misses Q4 EPS by 18c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. SPY
8. XYZ
9. ANET
10. CVS

Go back to Revance Therapeutics (RVNC) Misses Q4 EPS by 18c, Revenues Miss

Revance Releases Fourth Quarter and Full Year 2018 Results

February 26, 2019 4:05 PM EST

-Successful 2018: Positive SAKURA 3 topline data, Fosun and Mylan partnerships signed-

-On track to complete BLA submission with U.S. FDA for glabellar lines indication in the first half of 2019-

-Raised approximately $108 million net proceeds from public stock offering on January 22, 2019-

NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced results for the fourth quarter and full year ended December 31, 2018 and provided a business update.

Recent Highlights for... More